HEART FAILURE HOSPITALIZATION (HFH) DESPITE DIGOXIN THERAPY VERSUS NO HFH DESPITE PLACEBO IN THE DIGITALIS INVESTIGATION GROUP (DIG) TRIAL: INSIGHTS INTO RISK FACTORS FOR HFH IN HF AND REDUCED EJECTION FRACTION (HFREF)

Autor:	Phillip H. Lam, Daniel J. Dooley, Cherinne Arundel, Michelle White, Bertram Pitt, Wilbert S. Aronow, Javed Butler, Prakash Deedwania, Marc R. Blackman, Gregg Fonarow, Apostolos Tsimploulis, Aliy Ahmed, Charity J. Morgan, Wen-Chih Wu, Poonam Bhyan, Deepak L. Bhatt, Ioannis Kanonidis
Rok vydání:	2017
Předmět:	medicine.medical_specialty Ejection fraction biology Digoxin business.industry digestive oral and skin physiology Digitalis biology.organism_classification Placebo medicine.disease carbohydrates (lipids) Dig Internal medicine Heart failure polycyclic compounds Cardiology Medicine cardiovascular diseases Cardiology and Cardiovascular Medicine business medicine.drug
Zdroj:	Journal of the American College of Cardiology. 69:911
ISSN:	0735-1097
Popis:	Background: In the DIG trial, 6800 patients with HFrEF (EF≤45%) were randomized to receive either placebo (n=3403) or digoxin (n=3397) and followed for a mean of 37 months. Digoxin significantly reduced the risk of HFH by 28% (HR, 0.72; 95% CI, 0.66–0.79). However, 27% of patients in the digoxin
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::12e42158191e65fdd5bfbf72779183b1 https://doi.org/10.1016/s0735-1097(17)34300-0 Zobrazit plný text záznamu